公开(公告)号：EP1764102A1

公开(公告)日：2007-03-21

申请号：EP05755839.7

申请日：2005-07-01

申请人： DAIICHI PHARMACEUTICAL CO., LTD.

发明人： YANO, Emi ,  KOBAYASHI, Hideo, Daiichi Pharmaceutical Co., Ltd. ,  KIKUCHI, Hiroshi, Daiichi Pharmaceutical Co., Ltd. ,  YAMAGUCHI, Yuri, Daiichi Pharmaceutical Co., Ltd. ,  JINDO, Toshimasa, Daiichi Pharmaceutical Co., Ltd. ,  NISHIMOTO, N., Daiichi Pharmaceutical Co., Ltd.

IPC分类号： A61K31/4709 ,  A61K47/02

CPC分类号： A61K31/4709 ,  A61K9/0019 ,  A61K33/06 ,  A61K33/14 ,  A61K47/02 ,  A61K2300/00

摘要： The present invention relates to a pharmaceutical solution comprising the following components (A) and (B):
(A) a compound represented by the following formula (1):

or a salt thereof, or a hydrate thereof; and
(B) a multivalent metal compound, wherein molar ratio of the component (B) to component (A) (the multivalent compound / component (B)) is 0.01 to 0.7. A pharmaceutical solution adapted for intravascular administration containing the quinolone compound at a therapeutically sufficient amount is provided, and this solution exhibits reduced toxicity even when the multivalent metal compound were incorporated at a reduced amount.

摘要翻译： 本发明涉及包含以下组分（A）和（B）的药物溶液：（A）由下式（1）表示的化合物或其盐或其水合物： 和（B）成分（B）与成分（A）（多价化合物/成分（B））的摩尔比为0.01〜0.7的多价金属化合物。 提供了适于以治疗足够量含有喹诺酮化合物的血管内施用的药物溶液，并且即使当以降低的量掺入多价金属化合物时，该溶液也显示出降低的毒性。